查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1700181

2032 年皮癣菌病和灰指甲治疗市场预测：按产品类型、给药途径、治疗方法、分销渠道和地区进行的全球分析

Dermatophytic Onychomycosis Treatment Market Forecasts to 2032 - Global Analysis By Product Type, Route of Administration, Treatment, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球皮灰指甲治疗市场预计在 2025 年将达到 57 亿美元，到 2032 年将达到 108 亿美元，预测期内的复合年增长率为 9.5%。

皮癣菌灰指甲甲癣的治疗主要涉及医疗程序以根除感染指甲的真菌感染。这种疾病由皮癣菌引起，会导致指甲变厚、变色、变弱并最终脱落。治疗策略包括全身性抗真菌药物，如Terbinafine或Itraconazole，有助于从内部消除真菌感染，以及外用溶液，如环吡酮，涂抹于表面。对于顽固的感染疾病，雷射疗法或机械去爪等附加治疗方法可能有效。

根据美国疾病管制与预防中心 2022 年的数据，灰指甲（又称皮癣菌性灰指甲）每年在美国影响约 2,600 万人。

真菌性甲癣的盛行率不断上升

全球皮癣菌性灰指甲治疗市场受到真菌性甲癣感染疾病发病率不断上升的推动，尤其是在老龄化人口和免疫力缺乏的人群中。糖尿病和周边血管疾病等治疗会增加灰指甲的可能性，从而增加对有效治疗的需求。透过诊断宣传活动和远端医疗平台提高人们的意识，提高了早期发现率。长期穿着封闭式鞋子和接触公共空间等生活方式因素进一步加剧了感染的传播。此外，老年人口的增加，导致指甲变厚、血流量减少，加速了市场的成长。

治疗週期长，復发率高

治疗时间通常延长至6至12个月，导致患者违规并放弃治疗。局部治疗不能很好地渗透到指甲中，也不能完全根除真菌。由于生物膜的形成和孢子的持续存在，高復发率（20-30%）降低了患者对现有治疗方法的信心。长期治疗方法的经济负担（包括频繁就医）会阻碍患者坚持治疗。此外，非处方药对严重病例的疗效有限，也增加了患者的挫折感。

新型抗真菌疗法的进展

基于奈米粒子的局部製剂等创新技术增强了药物向指甲床的输送，提高了疗效并缩短了治疗时间。福斯拉康唑等肝毒性副作用较少的口服抗真菌药物的开发受到了患者的偏好。针对真菌细胞和生物膜的联合治疗有望降低復发率。製药公司和生物技术新兴企业之间的合作正在加速基因和雷射疗法的研究和开发。角蛋白干扰物等新机制的监管核准将进一步扩大治疗选择。

抗药性真菌的出现

过度使用Terbinafine等传统抗真菌药物导致皮癣菌产生抗药性，使治疗结果变得复杂。与抗生素研究相比，抗真菌药物的研究管道有限，延误了抗药性感染疾病的解决方案。真菌交叉抗药性机制正在降低新推出的治疗方法的疗效。识别抗药性菌株的诊断挑战阻碍了标靶治疗策略。此外，核准下一代抗真菌药物的监管障碍正在减缓市场对不断演变的病原体的反应。

COVID-19的影响

疫情扰乱了常规足病护理，延误了灰指甲的诊断和治疗。供应链中断影响了外用和口服抗真菌药物的供应，尤其是在新兴市场。加强卫生措施暂时降低了感染率，但却将医疗资源从较不紧急的情况中转移出去。疫情过后，远距皮肤科平台已成为远端咨询和配方更新的热门选择。復健工作优先考虑家庭疗法的研发投资，以满足患者对尽量减少就诊次数的偏好。

预计软膏和乳霜市场将在预测期内实现最大幅度成长

由于药膏和乳霜作为一线治疗药物和方便的商店治疗药物而广泛普及，预计在预测期内将占据最大的市场占有率。它的非侵入性使其对那些不愿接受全身性治疗和侵入性手术的患者俱有吸引力。渗透促进剂的创新，例如基于尿素的配方，可以提高对指甲的渗透性并提供更好的功效。与处方药相比，它们的成本效益导致其在低收入地区的采用率不断提高。然而，由于治疗严重感染疾病的局限性，其用途仅限于治疗轻度至中度病例。

预计在预测期内，製药业将以最高的复合年增长率成长。

预计在预测期内，疗程更短、治癒率更高的先进口服抗真菌药物的采用将实现最高的成长率。 VT-1161（奥替康唑）等较新的药物针对真菌特异酵素，从而最大限度地减少对人类细胞的毒性。对于难治性病例，全身性治疗的偏好日益增加，支持了这一领域的成长。新兴国家医疗支出的增加使得人们获得处方药的机会增加。此外，探索脉衝给药方案的临床试验提高了患者的依从性和治疗效果。

比最大的地区

在预测期内，由于热带气候和人口密度导致的真菌感染疾病高，预计亚太地区将占据最大的市场占有率。印度和中国等国家正在发展医疗基础设施并提高诊断能力。可支配收入的增加使得人们能够享受优质治疗，包括雷射治疗。政府为防治被忽视的热带疾病而做出的努力优先考虑抗真菌药物的研究和开发。在公共区域赤脚的习惯等文化因素也导致了该地区的需求。

复合年增长率最高的地区

由于其先进的医疗保健系统和患者对治疗方案的高度认识，预计北美将在预测期内见证最高的复合年增长率。各大製药公司实力雄厚，新疗法的推出正在加速。联合抗真菌药物的保险覆盖提高了其可负担性和普及性。糖尿病和肥胖症的发生率不断上升，导致灰指甲的流行。对稀有真菌孤儿药指定的监管激励将进一步推动市场成长。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场参与企业（最多 3 家公司）进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家进行市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 透过产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 主要研究资料
    • 先决条件

第三章市场走势分析

  • 介绍
  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球皮癣菌灰指甲治疗市场（依产品类型）

  • 介绍
  • 锭剂
  • 指甲油/亮油
  • 软膏和乳膏
  • 雷射治疗仪
  • 光动力动态（PDT）解决方案
  • 其他的

6. 全球皮癣菌灰指甲治疗市场（依给药途径）

  • 介绍
  • 口服
  • 话题
  • 其他的

7. 全球皮癣菌灰指甲治疗市场：治疗

  • 介绍
  • 药物
  • 雷射
  • 动态疗法
  • 其他的

8. 全球皮癣菌病灰指甲治疗市场（依分销管道）

  • 介绍
  • 医院药房
  • 零售药局
  • 网路药局
  • 药局

9. 全球皮癣菌病灰指甲治疗市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Bausch Health Companies
  • Galderma SA
  • Celtic Pharma
  • Anacor pharmaceuticals, Inc.
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline
  • Topica Pharmaceuticals, Inc.
  • Moberg Pharma AB
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd
  • Allergen, Inc.
  • Cipla Ltd
  • Medimetriks Pharmaceuticals Inc.
Product Code: SMRC29084

According to Stratistics MRC, the Global Dermatophytic Onychomycosis Treatment Market is accounted for $5.7 billion in 2025 and is expected to reach $10.8 billion by 2032 growing at a CAGR of 9.5% during the forecast period. The treatment of dermatophytic onychomycosis involves medical procedures designed to eradicate fungal infections that primarily affect the nails. This condition, caused by dermatophytes, results in nail thickening, discoloration, fragility, and in advanced cases, detachment. Management strategies include systemic antifungal medications like terbinafine and itraconazole, which help eliminate fungal infections internally, and topical solutions such as ciclopirox for surface application. For stubborn infections, additional therapies like laser treatment and mechanical nail removal may be used to enhance effectiveness.

According to the Centre for Disease Control and Prevention in 2022, nail fungus or dermatophytic onychomycosis affects around 26 million people in the U.S. each year.

Market Dynamics:

Driver:

Rising prevalence of fungal nail infections

The global dermatophytic onychomycosis treatment market is driven by the increasing incidence of fungal nail infections, particularly among aging populations and immunocompromised individuals. Conditions like diabetes and peripheral vascular disease heighten susceptibility to onychomycosis, fueling demand for effective treatments. Rising awareness through diagnostic campaigns and telehealth platforms has improved early detection rates. Lifestyle factors, such as prolonged use of occlusive footwear and exposure to communal spaces, further contribute to infection spread. Additionally, the growing geriatric demographic, prone to nail thickening and reduced blood flow, amplifies market growth.

Restraint:

Long treatment duration and high recurrence rates

Extended therapy periods, often spanning 6-12 months, lead to patient non-compliance and treatment abandonment. Topical solutions struggle with poor nail penetration, resulting in incomplete eradication of fungi. High recurrence rates (20-30%) due to biofilm formation and residual spores diminish patient confidence in existing therapies. The financial burden of prolonged treatment regimens, including frequent clinical visits, discourages adherence. Additionally, limited efficacy of over-the-counter products in severe cases exacerbates frustration among patients.

Opportunity:

Advancements in novel antifungal therapies

Innovations like nanoparticle-based topical formulations enhance drug delivery to the nail bed, improving efficacy and reducing treatment timelines. Development of oral antifungals with fewer hepatotoxic side effects, such as fosravuconazole, attracts patient preference. Combination therapies targeting both fungal cells and biofilms show promise in lowering recurrence rates. Partnerships between pharmaceutical firms and biotech startups accelerate R&D in gene-based and laser therapies. Regulatory approvals for novel mechanisms, such as keratin disruptors, further expand therapeutic options.

Threat:

Emergence of drug-resistant fungal strains

Overuse of conventional antifungals like terbinafine has led to resistant dermatophyte strains, complicating treatment outcomes. Limited antifungal drug pipelines compared to antibacterial research delay solutions for resistant infections. Cross-resistance mechanisms in fungi reduce the effectiveness of newly launched therapies. Diagnostic challenges in identifying resistant strains hinder targeted treatment strategies. Additionally, regulatory hurdles in approving next-generation antifungals slow market response to evolving pathogens.

Covid-19 Impact:

The pandemic disrupted routine podiatric care, delaying diagnoses and treatments for onychomycosis. Supply chain interruptions affected the availability of topical and oral antifungals, particularly in emerging markets. Increased focus on hygiene practices temporarily reduced infection rates but diverted healthcare resources away from non-urgent conditions. Post-pandemic, tele-dermatology platforms gained traction for remote consultations and prescription renewals. Recovery efforts prioritized R&D investments in home-applied therapies, aligning with patient preferences for minimal clinic visits.

The ointments & creams segment is expected to be the largest during the forecast period

The Ointments & Creams segment is expected to account for the largest market share during the forecast period ue to their widespread availability as first-line treatments and over-the-counter accessibility. Their non-invasive nature appeals to patients wary of systemic therapies or invasive procedures. Innovations in permeation enhancers, such as urea-based formulations, improve nail penetration for better efficacy. Cost-effectiveness compared to prescription drugs drives adoption in low-income regions. However, limitations in treating severe infections restrict their use to mild-to-moderate cases.

The drugs segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Drugs segment is predicted to witness the highest growth rate due to the introduction of advanced oral antifungals with shorter regimens and higher cure rates. Newer agents like VT-1161 (oteseconazole) target fungal-specific enzymes, minimizing human cell toxicity. Rising preference for systemic therapies in recalcitrant cases supports segment growth. Increased healthcare spending in emerging economies boosts access to prescription medications. Additionally, clinical trials exploring pulsed dosing regimens enhance patient compliance and outcomes.

Region with largest share:

During the forecast period, the Asia-Pacific region is expected to hold the largest market share due to high fungal infection prevalence linked to tropical climates and dense populations. Growing healthcare infrastructure in countries like India and China improves diagnostic capabilities. Rising disposable incomes enable access to premium therapies, including laser treatments. Government initiatives to combat neglected tropical diseases prioritize antifungal R&D. Cultural factors, such as barefoot practices in communal areas, also contribute to regional demand.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by advanced healthcare systems and high patient awareness of treatment options. Strong presence of key pharmaceutical players accelerates the launch of novel therapies. Insurance coverage for prescription antifungals enhances affordability and adoption. Increasing diabetic populations and obesity rates heighten susceptibility to onychomycosis. Regulatory incentives for orphan drug designations in rare fungal strains further propel market growth.

Key players in the market

Some of the key players in Dermatophytic Onychomycosis Treatment Market include Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy's Laboratories Ltd, Allergan, Inc., Cipla Ltd, and Medimetriks Pharmaceuticals Inc.

Key Developments:

In September 2024, Celtic Pharma announced OnychoCure, a dual-action oral + topical combo therapy targeting dermatophytes and biofilms. The regimen includes a once-weekly fluconazole tablet and a biofilm-disrupting ciclopirox spray, achieving 88% cure rates in Phase III trials.

In August 2024, Novartis AG partnered with Moberg Pharma AB to commercialize MOB-015, a patented topical amorolfine solution with microneedle-assisted application. The device ensures precise drug delivery to the nail matrix, reducing recurrence rates by 40% compared to conventional lacquers.

In July 2024, Pfizer Inc. introduced TerbinafineX, a topical nanoemulsion gel with deep nail penetration technology. The formulation uses lipid-based carriers to enhance delivery of terbinafine into the nail bed, achieving microbial eradication in 8 weeks. It is FDA-approved for diabetic patients, addressing a high-risk demographic.

Product Types Covered:

  • Tablets
  • Nail Paints/Lacquers
  • Ointments & Creams
  • Laser Therapy Devices
  • Photodynamic Therapy (PDT) Solutions
  • Other Product Types

Route of Administrations Covered:

  • Oral
  • Topical
  • Other Route of Administrations

Treatments Covered:

  • Drugs
  • Lasers
  • Photodynamic Therapy
  • Other Treatments

End Users Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Dermatophytic Onychomycosis Treatment Market, By Product Type

  • 5.1 Introduction
  • 5.2 Tablets
  • 5.3 Nail Paints/Lacquers
  • 5.4 Ointments & Creams
  • 5.5 Laser Therapy Devices
  • 5.6 Photodynamic Therapy (PDT) Solutions
  • 5.7 Other Product Types

6 Global Dermatophytic Onychomycosis Treatment Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Topical
  • 6.4 Other Route of Administrations

7 Global Dermatophytic Onychomycosis Treatment Market, By Treatment

  • 7.1 Introduction
  • 7.2 Drugs
  • 7.3 Lasers
  • 7.4 Photodynamic Therapy
  • 7.5 Other Treatments

8 Global Dermatophytic Onychomycosis Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Drug Stores

9 Global Dermatophytic Onychomycosis Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Bausch Health Companies
  • 11.2 Galderma S.A.
  • 11.3 Celtic Pharma
  • 11.4 Anacor pharmaceuticals, Inc.
  • 11.5 Johnson & Johnson
  • 11.6 Novartis AG
  • 11.7 Pfizer Inc.
  • 11.8 GlaxoSmithKline
  • 11.9 Topica Pharmaceuticals, Inc.
  • 11.10 Moberg Pharma AB
  • 11.11 Bayer AG
  • 11.12 Dr. Reddy's Laboratories Ltd
  • 11.13 Allergen, Inc.
  • 11.14 Cipla Ltd
  • 11.15 Medimetriks Pharmaceuticals Inc.

List of Tables

  • Table 1 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Tablets (2024-2032) ($MN)
  • Table 4 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Nail Paints/Lacquers (2024-2032) ($MN)
  • Table 5 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Ointments & Creams (2024-2032) ($MN)
  • Table 6 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Laser Therapy Devices (2024-2032) ($MN)
  • Table 7 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Photodynamic Therapy (PDT) Solutions (2024-2032) ($MN)
  • Table 8 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Other Product Types (2024-2032) ($MN)
  • Table 9 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 10 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Other Route of Administrations (2024-2032) ($MN)
  • Table 11 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Treatment (2024-2032) ($MN)
  • Table 12 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Drugs (2024-2032) ($MN)
  • Table 13 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 14 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 15 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Lasers (2024-2032) ($MN)
  • Table 16 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Phtodynamic Therapy (2024-2032) ($MN)
  • Table 17 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Other Treatments (2024-2032) ($MN)
  • Table 18 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 19 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 20 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 21 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 22 Global Dermatophytic Onychomycosis Treatment Market Outlook, By Drug Stores (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.